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Molecular epidemiology has significant potential in preventing cancer and other diseases caused
by environmental exposures (related to lifestyle, occupation, or ambient pollution). This approach
attempts to prevent cancer by incorporating laboratory methods to document the molecular dose
and preclinical effects of carcinogens, as well as factors that increase individual susceptibility to
carcinogens. Recently we have carried out validation studies of biologic markers such as
carcinogen-DNA and carcinogen-protein adducts, gene and chromosomal mutations, alterations
in target oncogenes or tumor suppressor genes, polymorphisms in putative susceptibility genes
(individual P450s, glutathione transferase Ml), and serum levels of micronutrients. This research
involves adults, infants, and children exposed to varying levels of carcinogens, as well as cancer
cases and controls. On a group level, dose-response relationships have frequently been seen
between various biomarkers and environmental exposures such as polycyclic aromatic
hydrocarbons, cigarette smoke (active and passive), and ambient indoor and workplace air
pollution. However, there is significant interindividual variation in biomarkers that appears to
reflect a modulating effect on biomarkers (hence potential risk) by genetic and acquired
susceptibility factors. Ongoing retrospective and nested case-control studies of lung and breast
cancer are examining the association between biomarkers and cancer risk. Results of these
studies are encouraging; they suggest that biomarkers, once validated, can be useful in
identifying populations and individuals at risk in time to intervene effectively. Environ Health
Perspect 104(Suppl 3):441-443 (1996)
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Introduction
The following discussion highlights recent and in intervention such as exposure
molecular epidemiologic research on the reduction and chemoprevention.
use ofbiologic markers in the prevention Effects of Environmental ofenvironmental carcinogenesis and repro- Effect s o nHumanmen t h ductive toxicity. The research explores the Exposures on Human Heafth
potential of molecular epidemiology as an Clear effects of environmental exposures
early warning system ofadverse effects, as a on biomarkers have been seen in active and
means ofunderstanding variability in risk, passive smokers, workers, and others
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exposed to ambient pollution and carcino-
gens in the diet. For example, serial sam-
ples from 40 heavy smokers (>1 pack/day
for >1 year) enrolled in a smoking cessa-
tion program were assayed for cotinine,
polycyclic aromatic hydrocarbon (PAH)-
DNA, 4-aminobiphenyl-hemoglobin (4-
ABP-Hb) adducts, and glycophorin A
(GPA) mutations. Blood samples were
taken while smoking and at 10 weeks and
8 and 14 months after quitting. Cotinine
was used to assess compliance with the ces-
sation protocol. A significant reduction in
mean PAH-DNA and 4-ABP-Hb adducts
was observed following cessation in all per-
sons who were cotinine-verified quitters
(<25ng/ml) for .8 months (p<0.05).
Neither GPA N/0 nor GPA N/N muta-
tions were significantly reduced following
smoking cessation, but results are limited
by the small number (n= 18) ofheterozy-
gous individuals studied (1).
Effects of environmental exposures
(smoking, air pollution, and diet) on PAH-
DNA damage and CYPIAI gene induction
(elevated mRNA) and the modulation of
DNA damage by the CYPJA1 Msp I vari-
ant genotype were evaluated in two groups
from Poland: 70 mother/child pairs from
Krakow, a city with elevated air pollution;
and 90 pairs from Limanowa, a less pol-
luted area (2). The human CYPIAI gene
codes for an inducible enzyme system
involved in biotransformation of certain
xenobiotics including PAHs; some of the
metabolites are carcinogenic and muta-
genic. Maternal leukocyte PAH-DNA
adduct levels were significantly increased
with cigarette smoking (active and passive)
and workplace exposures (p<0.05). Within
Krakow, there was an apparent dose
response in maternal adducts with increas-
ing ambient pollution at the women's
residences; the trend was significant
for women not employed away from the
home (p<0.05).
Similar to results seen with maternal
adduct levels, placental (fetal) CYPlAl
mRNA was increased with both smoking
and air pollution (3). The major deter-
minant of CYPlAl mRNA levels in pla-
cental tissue was active cigarette smoking
(p<0.001). A marginal increase in CYPlAl
mRNAwith environmental tobacco smoke
(ETS) exposure was evident. There was
a dose response in placental CYPlAl
mRNA levels with ambient pollution at
the women's places of residence within
Krakow; the association was significant
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among newborns ofwomen not employed
away from home (p<0.05, controlling for
smoking status, diet, place of residence,
and coal use) (3).
Among infants with induced placental
CYPIAI, adducts in infant cord blood were
inversely correlated with the levels of
CYPlAI induction/activity (2). Adduct
levels in infant cord leukocytes were higher
than adduct levels in paired maternal sam-
ples, both in the total cohort (7.9 ±9.9 vs
5.9 ± 8.2 per 108 nucleotides) and after
stratification by placental CYPIAI induc-
tion. These results indicate that the pla-
centa, bymetabolizing PAH, decreases their
transfer to the fetus and suggest increased
susceptibility of the developing fetus to
PAH-DNA adduct formation. The higher
adduct levels in newborn samples compared
to paired maternal samples is particularly
striking, given evidence from experimental
bioassays that transplacental exposure to
PAH is at least an order ofmagnitude lower
than maternal exposure (4,5).
In addition to using biomarkers as
environmental dosimeters, several studies
have shown associations between specific
biomarkers and reproductive effects (6). In
a prior study, a highly significant associa-
tion was found between decreased birth
weight and the level ofsmoking-related
adducts in placental tissue collected from
30 smoking mothers (7). By contrast, no
association was seen between decreased
birth weight and either intensity ofsmok-
ing exposure assessed by questionnaire data
or biochemical measures ofsmoking expo-
sure (cotinine, thiocyanate, and carboxyhe-
moglobin). In the study ofPolish mothers
and newborns described above, an inverse
association was seen between infant cord
PAH-DNA adduct levels (as a biologically
relevant dosimeter offetal exposure) and
the development ofthe infant. The inverse
association was highly significant for infant
head circumference at birth.
Biomarkers as Indicators
of Individual Susceptibility
and Potential Risk
To better understand the role of environ-
mental and genetic factors in lung cancer,
we have measured DNA damage from
PAHs and a polymorphism in the CYPIAI
and glutathione S-transferase (GSTMI)
genes. There is prior evidence that the
GSTMI null (0/0) genotype is associated
both with decreased ability to detoxify
PAH and other carcinogens and with
increased risk oflung cancer. Leukocytes
from 119 non-small cell carcinoma lung
cancer cases and from 98 noncancer con-
trols were analyzed for PAH-DNA adducts
by enzyme-linked immunoadsorbent assay
(ELISA) and for GSTMI genotype by
polymerase chain reaction (PCR) (8). After
adjustment for potential confounders (age,
smoking, etc.), adducts were higher in
cases (p<0.01) than in controls. Adducts
were increased in smokers and ex-smokers
compared to nonsmokers among cases and
controls (p<0.05). Adducts also increased
with cigarettes per day among the 51 cases
who were current smokers (p= 0.05) but
not among the smoking controls. Fifty-
seven percent ofcases had the GSTMI 0/0
genotype compared to 41% of controls
(p<0.05). After adjusting for confounders,
odds ratios for adducts and GSTMI geno-
type were 6.8 (1.6-29.6, p<0.01) and 1.93
(1.1-3.4, p<0.05), respectively. When the
subjects were classified by adducts (high/
low) and GSTMI genotype (0/0 vs 0/+ or
+/+), the risk was 12-fold higher for those
individuals with both high adducts and
GSTMI 0/0 compared to those without
either factor. This approach may be useful
in constructing a risk model for lung
cancer and ultimately in applying it to
prevention through the identification of
individuals at greatest risk (8).
In the study of heavy smokers men-
tioned above, three genotypes, (CYPIAJ
exon 7 rare allele, CYPIAI Msp I restric-
tion fragment length polymorphism
[RFLP], and GSTMI) were measured by
PCR in a total of 159 subjects (unpub-
lished data). Eighteen percent had the
Msp I RFLP (+/+ or +/-), 6% had the exon
7 rare allele (+/+ or +/-), and 46% had the
GSTMI null genotype (0/0). Mean DNA
adduct levels were 2-fold higher in subjects
with the CYPIAI exon 7 polymorphism
than in those without the polymorphism
and were unchanged by adjustment for
smoking. Mean DNA adduct levels were
also higher in the subjects with the
CYPIAI Msp I polymorphism than in
those without, but the difference was not
significant. GSTMI was not associated
with DNA adduct formation before or
after adjustment for amount ofsmoking.
These findings in healthy smokers support
the hypothesis that one or more of these
metabolic genes are related to carcinogen
binding to DNA and possibly to an
increased relative risk for lung cancer
(unpublished data).
The association between the CYPIAI
Msp I, RFLP, and PAH-DNA adduct
levels are also being evaluated in our study
of Polish mothers and newborns described
above. Preliminary analyses show the poly-
morphism to be a significant determinant
of PAH-DNA adduct levels in placental
tissue, controlling for smoking status,
place ofresidence, home and occupational
exposures, and diet.
Biomarkers in Detecting
Efficacy of Intervention
xposure Reduction
Carcinogen-DNA adducts and somatic
gene mutations at the hypoxanthine gua-
nine phosphoribosyltransferase (HPRT)
locus were evaluated in peripheral leuko-
cytes ofworkers in an iron foundry with
exposure to benzo[a]pyrene (B[a]P) and
other PAHs (9). During the 2-year study
period, B[a]P exposure declined by
approximately 40%, from a maximum
of 60 ng/m3 in the first year to below
36 ng/m3 1 year later. A total of67 persons
were sampled in November/December
of the two successive study years; 24 of
them gave two samples 1 year apart. The
biomarkers included carcinogen-DNA
adducts in leukocytes (PAH-DNA mea-
sured by an immunoassay, aromatic DNA
by the 32P-postlabeling method) and
HPRTmutation in lymphocytes. After
adjusting for smoking, levels of PAH-
DNA, aromatic DNA, and HPRTmuta-
tion increased with exposure among the 67
workers sampled during the 2-year period
(p<0.05). However, the markers showed a
differential response to the change in expo-
sure, consistent with their individual biol-
ogy. For example, among the 24 workers
sampled in both years, carcinogen-DNA
adducts (which have a half-life on the order
ofseveral months) were markedly reduced
from the first to the second year (PAH-
DNA, 6.2 vs 2.3/108; aromatic DNA, 2.5
vs 1.4/108; p<0.01). HPRTMf (a longer-
lived marker) was somewhat less affected
by the decline in exposure (1.3 vs 0.8;
p<0.05). Moreover, in the second year,
several long-term workers had low levels of
adducts but elevated HPRTMf. Thus,
PAH-DNA and HPRTMf were highly
correlated in the first year (n =17; r =0.67;
p<0.01) but not in the second year or in
the 2 years combined. However, when
analysis was restricted to workers with
detectable levels ofadducts (who included
the more highly exposed workers), the
correlation was significant between
PAH-DNA and HPRT(n = 19; r =0.67;
p= 0.002). In contrast to PAH-DNA,
aromatic DNA adducts and HPRTwere
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not correlated in either year. These results
suggest a molecular link between somatic
gene mutation and PAHs (9).
In the above-mentioned study of
heavy smokers, the substantial reduction
(50-75%) in PAH-DNA and 4-ABP-Hb
adduct levels after quitting smoking indi-
cates that these carcinogen adducts provide
molecular evidence ofthe benefits ofsmok-
ing cessation (1). The biomarkers can there-
fore be useful in compliance ascertainment
and feedback.
Chemoprevention
Biologic markers already play an important
role in the evaluation ofchemopreventive
agents, specifically in Phase II trials (10-12).
The most commonly used genetic markers
in current trials involving lung and upper
aerodigestive tract tumors include micronu-
clei, DNA content, genetic alteration in
oncogenes, and markers ofproliferation,
growth regulation and differentiation (12).
Our research also suggests that addi-
tional earlier biomarkers such as carcino-
gen-DNA adducts can be useful in
intervention studies ofexposed or at risk
populations. Several recent studies have
examined whether baseline levels of
micronutrients (vitamins C, E, ,-carotene,
or retinol) in the serum of persons who
have not been treated with chemopreven-
tion are inversely related to genetic damage
(9,13). In a cross-sectional study of 63
heavy smokers, the serum concentrations
of a-tocopherol (cholesterol-adjusted),
ascorbic acid, 1-carotene, and retinol were
evaluated in relationship to the levels of
PAH-DNA adducts in lymphocytes mea-
sured in the same individuals (14). All of
the participants were current smokers, and
90% had smoked one or more packs per
day for at least 10 years. A significant
inverse correlation was found between
serum a-tocopherol and PAH-DNA
adducts. Although the relationship was not
statistically significant, serum ascorbic acid,
1-carotene, and retinol were inversely
correlated with adducts.
In the smoking cessation cohort
described above, both a-tocopherol and
retinol were inversely correlated with
PAH-DNA adducts at baseline while sub-
jects were smoking and in follow-up sam-
ples after cessation. In addition, the
GSTMI genotype modified the relation-
ship between DNA adducts and a-tocoph-
erol. Indicating an interaction between two
susceptibility factors, a-tocopherol had a
strong inverse effect in subjects lacking the
GSTMI gene, whereas in subjects with the
gene, there was no signficant association
(unpublished data).
Once validated, biologic markers can
be incorporated into a wide variety of
intervention and chemoprevention studies
ofsmokers, workers, and other populations
at high risk ofdisease.
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